Haisco Pharmaceutical Group Co Ltd (Haisco Pharma) is a pharmaceutical company that produces and sells chemical drugs. The company offers drugs in the areas of narcotic analgesics, endocrine system, enteral and parenteral nutrition, neuropsychiatric, cardiovascular, cancer-related drugs and digestive liver disease, among others. Haisco Pharma's product range covers anesthesia and analgesia, parenteral nutrition, tumor antiemetic, liver disease treatment, digestive system, nervous system, anti-infection, and other sub-fields. The company conducts research and development of drugs for various diseases. It operates offices in Shannan and Chengdu, China. Haisco Pharma is headquartered in Shannan, Tibet, China.
Headquarters
China
Address
No. 17, Sanxiang Avenue, Zedang Town, Shannan, Tibet, 856000
Website
www.haisco.com
Telephone
86 893 7834865
No of Employees
4,726
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002653 (SHE)
Revenue (2022)
$448.1M
8.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-19.7%
(2022 vs 2021)
Market Cap*
$3.6B
Net Profit Margin (2022)
XYZ
-26.1%
(2022 vs 2021)
* As of and is in US$
Haisco Pharmaceutical Group Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Narcotic Analgesics Drugs |
| Endocrine System Drugs |
| Enteral and Parenteral Nutrition Drugs |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In March, the company signed an agreement to sell its the US, Singapore subsidiaries to Haisco Pharma's unit. |
| 2023 | Contracts/Agreements | In March, the company signed a contract with Aquestive Therapeutics, Inc of the United States for the treatment of amyotrophic lateral sclerosis. |
| 2022 | Others | In April, the company received the Notice of Approval for the Clinical Trial of the Innovative Drug HSK36273 for Injection issued by the State Drug Administration. |
Competitor Comparison
| Key Parameters | Haisco Pharmaceutical Group Co Ltd | Jiangsu Hengrui Medicine Co Ltd | Zhangzhou Pien Tze Huang Pharmaceutical Co Ltd | Luye Pharma Group Ltd | CSPC Innovation Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shannan | Lianyungang | Zhangzhou | Yantai | Shijiazhuang |
| State/Province | Tibet | Jiangsu | Fujian | Shandong | Hebei |
| No. of Employees | 4,726 | 20,636 | 2,720 | 5,005 | 1,945 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Wang Junmin | Chairman | Executive Board | 2010 | 55 |
| Zheng Wei | Director; Deputy General Manager | Executive Board | 2020 | 53 |
| Fan Xiulian | Managing Director | Executive Board | 2019 | 60 |
| Wang Meng | Deputy General Manager; Secretary | Senior Management | 2015 | 38 |
| Duan Peng | Director - Financial | Senior Management | 2016 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward